What is a consequence of using Nitroglycerin with PDE inhibitors?

What is a consequence of using Nitroglycerin with PDE inhibitors?

• A. Enhanced therapeutic effect
• B. Increased risk of hypotension
• C. Reduced heart rate
• D. Improvement of vascular tone

Answer: (B)

The use of Nitroglycerin in combination with phosphodiesterase (PDE) inhibitors can lead to an increased risk of hypotension. Nitroglycerin acts as a vasodilator, relaxing blood vessels and lowering blood pressure. PDE inhibitors, such as sildenafil, tadalafil, and vardenafil, also have vasodilating effects which increase the levels of cyclic GMP (cGMP) in vascular smooth muscle, leading to further vasodilation. When combined, the effects of these two drug classes can amplify each other, creating a significant drop in blood pressure. This effect can result in symptoms such as dizziness, lightheadedness, and in severe cases, syncope or loss of consciousness. This serious interaction is why it is critical to avoid the concurrent use of Nitroglycerin and PDE inhibitors. Understanding this interaction is essential for ensuring patient safety and effective management of cardiovascular conditions.

The use of Nitroglycerin in combination with phosphodiesterase (PDE) inhibitors can lead to an increased risk of hypotension. Nitroglycerin acts as a vasodilator, relaxing blood vessels and lowering blood pressure. PDE inhibitors, such as sildenafil, tadalafil, and vardenafil, also have vasodilating effects which increase the levels of cyclic GMP (cGMP) in vascular smooth muscle, leading to further vasodilation.

When combined, the effects of these two drug classes can amplify each other, creating a significant drop in blood pressure. This effect can result in symptoms such as dizziness, lightheadedness, and in severe cases, syncope or loss of consciousness. This serious interaction is why it is critical to avoid the concurrent use of Nitroglycerin and PDE inhibitors. Understanding this interaction is essential for ensuring patient safety and effective management of cardiovascular conditions.